Clinical Value of Cerebrospinal Fluid ctDNA in Patients 
with Non-small Cell Lung Cancer Meningeal Metastasis

• Published in: Zhongguo fei ai za zhi Vol. 23; no. 12; pp. 1039 - 1048
• Main Authors: Zhang, Kunyu, Dai, Zhaoxia, Liu, Siya, Li, Dan, Yang, Dafu, Cui, Saiqiong
• Format: Journal Article
• Language: Chinese
• Published: China Chinese Anti-Cancer Association Chinese Antituberculosis Association 01.12.2020; Chinese Anti-Cancer Association; Chinese Antituberculosis Association
• Subjects: Adult; Aged; Biopsy; Brain cancer; Cancer therapies; Carcinoma, Non-Small-Cell Lung - blood; Carcinoma, Non-Small-Cell Lung - cerebrospinal fluid; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; circulating tumor dna; Circulating Tumor DNA - blood; Circulating Tumor DNA - cerebrospinal fluid; Circulating Tumor DNA - genetics; Deoxyribonucleic acid; DNA; FDA approval; Female; Humans; Lung cancer; lung neoplasms; Lung Neoplasms - blood; Lung Neoplasms - cerebrospinal fluid; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Magnetic resonance imaging; Male; meningeal metastasis; Meningeal Neoplasms - cerebrospinal fluid; Meningeal Neoplasms - genetics; Meningeal Neoplasms - secondary; Metastasis; Middle Aged; Mutation; Patients; Plasma; response evaluation; Tumors; Meningeal metastasis; Circulating tumor DNA; Response evaluation; Lung neoplasms
• ISSN: 1009-3419; 1999-6187; 1999-6187
• DOI: 10.3779/j.issn.1009-3419.2020.102.42

The mortality rate of lung cancer meningeal metastasis is extremely high. Circulating tumor DNA (ctDNA) has been confirmed to be contain the genomic alterations present in tumors and has been used to monitor tumor progression and response to treatments. Due to the presence of blood-brain barrier and other factors, peripheral blood ctDNA cannot reflect the information of brain lesions for patients with meningeal metastases. However, cerebrospinal fluid ctDNA as a test sample can better reflect the genetic status of intracranial tumors and guide clinical targeted treatment of intracranial lesions. This study explored the feasibility of cerebrospinal fluid ctNDA for evaluating non-small cell lung cancer (NSCLC) meningeal metastasis and the potential clinical value of cerebrospinal fluid ctDNA detection in NSCLC meningeal metastasis. A total of 21 patients with NSCLC meningeal metastasis were included. Tumor genomic variation was performed on the cerebrospinal fluid and peripheral blood samples of patients by sec